Edward Price, President & CEO, SEQENS N.A. and member of the Bulk Pharmaceuticals Task Force, an affiliate of SOCMA testified to the Subcommittee on Health of the Committee on Energy and Commerce on October 30.
Categories for Active Pharmaceutical Ingredients
Edward Price, President and CEO, SEQENS N.A. and a member of SOCMA’s Bulk Pharmaceutical Task Force, today called for reasonable regulations and increased collaboration between stakeholders during testimony before the House Committee on Energy & Commerce hearing on Pharmaceutical Supply Chains in a Global Economy.
After almost three weeks, the government shutdown is having a ripple affect on the Food and Drug Administration’s (FDA) submission of Generic Drug User Fee Act (GDUFA) and other pharmaceutical supply chain user fee programs overseen by the Agency.
SOCMA’s BPTF Executive Director Shares Perspective on API Supply Issues, Impact on PharmaChem Sector
ARLINGTON, VA – John DiLoreto, Executive Director of the Bulk Pharmaceuticals Task Force and advisor to SOCMA’s PharmaChem Sector, delivered a fresh perspective on the pharmaceutical supply problem as a trickle-down effect of multiple factors within the fine and specialty chemical sector during a panel discussion on Manufacturing and Supply Challenges in Washington, D.C.
ARLINGTON, VA – John DiLoreto, Executive Director of the Bulk Pharmaceuticals Task Forceand advisor to SOCMA’s PharmaChem Sector, will participate in a panel discussion about Manufacturing and Supply Challenges at a U.S. Food & Drug Administration event sponsored by Duke Margolis Center for Health Policy.
BPTF Hosts Annual Spring Meeting to Discuss Issues Impacting Active Pharmaceutical Ingredient Manufacturers
The Bulk Pharmaceuticals Task Force (BPTF) hosted its annual Spring Meeting here at the Society for Chemical Manufacturers and Affiliates (SOCMA) headquarters to discuss key issues and challenges facing the pharmaceutical industry and hear from industry experts.